Parliament Workbench
Data: Motions & questions to 19 Nov 2026 · Votes to 12 Nov 2026

Standard Motion · S2M-05439 · Session 2

Protect the Use of Xolair for Asthma Sufferers

Lodged by Shona Robison SNP Lodged 18 Jan 2007 3 supporters

The motion

That the Parliament regrets the decision by the Scottish Medicines Consortium (SMC) not to recommend the use of Xolair for people with severe allergic asthma; notes that, for 90% of people with asthma, their asthma symptoms should be controllable if they are on the right levels of existing asthma drugs but, for those who have difficult-to-control asthma and continue to experience poor quality of life and continuous symptoms, Xolair is the only treatment that may be able to reduce the impact of asthma on their lives by reducing symptoms and hospitalisation; notes that Xolair has been shown to reduce emergency admissions to hospital, reduce asthma exacerbations, improve lung function and improve quality of life, and urges the SMC to reconsider its decision not to recommend Xolair in Scotland, a drug which has been described by Donna Covey, Chief Executive of Asthma UK, as “the only hope that some people in Scotland currently have.”

Signatures by party

3 MSPs besides the lodger · 1 from other parties
SNP 2LD 1

Party on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions

Vote

No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.

Supporters

3 MSPs

SNP 2 LD 1

Show all 3 supporters by party

SNP 2

LD 1

Party shown is each supporter’s party when the motion was published.

In the Official Report

No contribution in the Official Report cites S2M-05439 by reference.